Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avid Radiopharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Avid Radiopharmaceuticals Inc. has two radiolabeled compounds in clinical trials that specifically and sensitively bind amyloid beta. The company intends to make these products available to pharmaceutical companies that are developing anti-amyloid therapeutics for Alzheimer's disease. Avid's own first commercial product for AD is still in preclinical development and will be visualized using positron emission computed tomography.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091256

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel